ArticleInternational journal of molecular sciences2026
Changes in Blood Cells and Complements During Relapse Prevention Therapies for Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder.
Hiroshi Kuroda, Kazuo Fujihara, Kimihiko Kaneko, Yoshiki Takai, Yuki Matsumoto, Mizuki Otomo, Naoya Yamazaki, Shu Umezawa, Naoki Yamamoto, Naohiro Sakamoto and 6 more
Abstract read
In one paragraphArticle in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
16 authors.
Hiroshi KurodaDepartment of Multiple Sclerosis Therapeutics, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan.ORCID 0000-0003-0421-3110 Kazuo FujiharaDepartment of Multiple Sclerosis Therapeutics, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan.ORCID 0000-0002-3096-4156 Kimihiko KanekoDepartment of Neurology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan.
Yoshiki TakaiDepartment of Neurology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan.
Yuki MatsumotoDepartment of Neurology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan.ORCID 0000-0003-0163-8105 Mizuki OtomoDepartment of Neurology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan.
Naoya YamazakiDepartment of Neurology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan.ORCID 0000-0002-9158-5686 Shu UmezawaDepartment of Neurology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan.
Naoki YamamotoDepartment of Neurology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan.
Naohiro SakamotoDepartment of Neurology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan.ORCID 0009-0008-7256-2308 Chihiro NamatameDepartment of Neurology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan.
Hirohiko OnoDepartment of Neurology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan.
Shuhei NishiyamaDepartment of Neurology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan.ORCID 0000-0002-0248-1595 Toshiyuki TakahashiDepartment of Neurology, National Hospital Organization Yonezawa National Hospital, Yonezawa 992-1202, Japan.
Tatsuro MisuDepartment of Neurology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan.ORCID 0000-0002-7311-2578 Masashi AokiDepartment of Neurology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan.
Funding
The Ministry of Education, Culture, Sports, Science and Technology of Japan 19K07953, 17H04192
6 · The paper itselfAbstract
In this study, blood cell counts and serum C3, C4, and CH50 values at baseline and after more than 6-month drug use were measured to elucidate changes in blood cells and complements during relapse prevention therapies for aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4+ NMOSD). A total of 70 patients with AQP4+ NMOSD (87% female, median age 56 years) were enrolled. They were divided into the following treatment groups: glucocorticoids and/or immunosuppressants (GC/IS,
Indexed as
Antibodies, MonoclonalImmunotherapyInterleukin-6 InhibitorsNeuromyelitis OpticaAdultAgedAged, 80 and overAutoantibodiesBlood Cell CountComplement C3Complement C4Complement C5Complement Hemolytic Activity AssayFemaleHumansMaleanti-aquaporin 4 autoantibodyAntibodies, MonoclonalAutoantibodiesComplement C3Complement C4Complement C5Interleukin-6 InhibitorsC3C4CH50neutrophilplateletsatralizumab
Identifiers
PMID41596603
PMCPMC12841590
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390